[HTML][HTML] Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Lung cancer is the leading cause of cancer related deaths in Canada with non-small cell
lung cancer (NSCLC) being the predominant form of the disease. Tumor characterization …
lung cancer (NSCLC) being the predominant form of the disease. Tumor characterization …
[HTML][HTML] EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta …
I Michelon, M Vilbert, CE do Rego Castro… - Journal of Personalized …, 2024 - mdpi.com
We performed a systematic review and meta-analysis to assess the efficacy of EGFR-
tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung …
tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung …
[HTML][HTML] The effects and molecular mechanisms of MiR-106a in multidrug resistance reversal in human glioma U87/DDP and U251/G cell lines
Q Wang, Z Wang, LY Chu, X Li, P Kan, X Xin, Y Zhu… - PLoS …, 2015 - journals.plos.org
Chemotherapy resistance is one of the major obstacles to effective glioma therapy.
Currently, the mechanism underlying chemotherapy resistance is unclear. A recent study …
Currently, the mechanism underlying chemotherapy resistance is unclear. A recent study …
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after …
H Yang, X Yang, Y Zhang, X Liu, Q Deng, M Zhao… - Targeted Oncology, 2015 - Springer
Limited treatment options are available for lung cancer with brain metastases. Recent
reports indicated that erlotinib and pemetrexed had synergistic effects in lung …
reports indicated that erlotinib and pemetrexed had synergistic effects in lung …
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors
L Landi, M Tiseo, R Chiari, S Ricciardi, E Rossi… - Clinical lung cancer, 2014 - Elsevier
Background The purpose of this study was to evaluate the efficacy of afatinib in EGFR-
mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials …
mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials …
Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
J Xu, X Liu, S Yang, X Zhang, Y Shi - OncoTargets and therapy, 2017 - Taylor & Francis
Background Treatment failure frequently occurs in patients with epidermal growth factor
receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who respond to EGFR tyrosine …
receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who respond to EGFR tyrosine …
[HTML][HTML] Effectiveness and safety of EGFR-TKI rechallenge treatment in elderly patients with advanced non-small-cell lung cancer harboring drug-sensitive EGFR …
Y Yamada, H Imai, T Sugiyama, H Minemura… - Medicina, 2021 - mdpi.com
Background and Objectives: Epidermal growth factor receptor–tyrosine kinase inhibitors
(EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non …
(EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non …
Study of efficacy and safety of pulsatile administration of high‐dose gefitinib or erlotinib for advanced non‐small cell lung cancer patients with secondary drug …
Y Zhu, Y Du, H Liu, T Ma, Y Shen, Y Pan - Thoracic cancer, 2016 - Wiley Online Library
Background The objective of the study was to observe the efficacy and safety of pulsatile
administration of high‐dose gefitinib or erlotinib in patients with advanced non‐small cell …
administration of high‐dose gefitinib or erlotinib in patients with advanced non‐small cell …
Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFR activating mutations
Y Inutsuka, E Iwama, Y Shiraishi, Y Yoneshima… - Respiratory …, 2024 - Elsevier
Background Osimertinib shows pronounced efficacy for EGFR mutation–positive non–small
cell lung cancer (NSCLC) including associated central nervous system (CNS) metastases …
cell lung cancer (NSCLC) including associated central nervous system (CNS) metastases …
[HTML][HTML] Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC)
L Chen, R Chen, Z Zhu, Y Zhang, Z Wen… - Chinese Journal of …, 2014 - ncbi.nlm.nih.gov
Purpose A number of different clinical characteristics have been reported to singly correlate
with therapeutic activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …
with therapeutic activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …